Summary
Philip Morris International Inc. (PM) has announced a significant strategic move through its wholly-owned subsidiary, PMI Global Services, Inc., to acquire Fertin Pharma A/S for an enterprise value of approximately USD 820 million. Fertin Pharma is a Denmark-based company specializing in the development and manufacturing of pharmaceutical and nutraceutical products, with a particular focus on oral and intra-oral delivery systems. This acquisition signals PM's continued diversification efforts beyond traditional tobacco products and into reduced-risk alternatives and adjacent health and wellness sectors. The transaction is subject to customary closing conditions, including antitrust and governmental approvals, with an expected closing around October 6, 2021. The agreement includes standard representations, warranties, and covenants, as well as non-compete and non-solicitation clauses for the sellers. This acquisition is a key step for Philip Morris International as it aims to transform its business model and expand its presence in the rapidly growing health and wellness market.
Key Highlights
- 1PMI Global Services, Inc. is acquiring Fertin Pharma A/S for an enterprise value of DKK 5,121,500,000 (approx. USD 820 million).
- 2Fertin Pharma specializes in pharmaceutical and nutraceutical products with oral and intra-oral delivery systems.
- 3The acquisition aligns with PM's strategy of diversifying beyond traditional tobacco into health and wellness categories.
- 4The transaction is expected to close on or around October 6, 2021, subject to regulatory approvals.
- 5The agreement includes customary conditions, representations, warranties, and covenants, along with post-closing restrictions on sellers.
- 6The deal involves standard indemnification obligations for sellers, with an emphasis on warranty and indemnity insurance.
- 7PMI is actively pursuing growth in non-combustible product categories and reduced-risk alternatives.